US Biotechnology and Pharmaceuticals: GLP-1 TRx trends from the month and last week

Research evidence excerpt

US Biotechnology and Pharmaceuticals: GLP-1 TRx trends from the month and last week

Viewpoint |

31 Jul 2026 07:21:07 ET │ 15 pages

US Biotechnology and

Pharmaceuticals

GLP-1 TRx trends from the month and last week

Geoff Meacham, Ph.D. AC

CITI'S TAKE +1-404-443-4701

geoffrey.meacham@citi.com

We examined GLP-1 TRx trends over the past four weeks to assess y/y

market changes. Collectively, TRx is 4.5% vs 0.6% prior as oral options Mary Kate Davis

broaden and reshape the market. Lilly's tirzepatide now holds 56.2% +1-212-816-9602

market share of total GLP-1 TRx, with share 0.5% over the four week period; mary.kate.davis@citi.com

compared to 48.4%/-1.1% last year. Comparatively, Novo’s semaglutide has

37.1% share remaining relatively flat (0.1% growth). Indeed, this week’s focus Jarwei Fang

remains on upcoming 2Q reporting (see our preview here) and Foundayo +1-212-816-5127

given recent approval (note), granted early but the script trends continue to jarwei.fang@citi.com

build (29.3K; potential gap in telehealth) after becoming available 4/9 and

Nishant Gandhi, Ph.D.we look for further growth to develop the oral competitive market (Wegovy

pill 171.7K). W/w changes below. +1-212-816-2513

nishant.gandhi@citi.com

Oral market taking shape with Foundayo and Wegovy pill — Interestingly oral

Wegovy scripts now make up 34% of total Wegovy scripts (last week of 35%; +0%

w/w) suggesting preferences for oral formulations. After the commercial launch of

Foundayo 4/9, we note scripts continue to build with 29.3K (see takeaways here;

and total script count Figure 11). As IQVIA capture for Foundayo continues to solidify,

we note there may be a gap in telehealth capture as management previously

confirmed ~20k on Foundayo since launch, April 6 through earnings call on April 30